UCLA Jonsson Comprehensive Cancer Center researchers leading a meta-analysis of seven randomized trials found an "unexpected result": Although Black men appeared to have more aggressive disease when they enrolled in clinical ...
Dec 29, 2021
1
72
Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading, could halve the risk of death from the disease.
Dec 28, 2021
0
35
More than one in 10 patients with localized prostate cancer experience treatment-related regret—a sense of disappointment with their treatment compared to other treatment options—according to a recent study published ...
Dec 13, 2021
0
0
Restrictions in access to care during the COVID-19 pandemic caused disruptions in the treatment of cancer and other conditions. A new study now indicates that the pandemic also likely caused new cancer diagnoses to be delayed, ...
Dec 6, 2021
0
3
Since 1971, when the U.S. government made defeating cancer a goal and put major funding behind it, death rates for many cancers have plummeted, but some are increasing, according to a new American Cancer Society report.
Nov 11, 2021
0
11
Researchers at the University of East Anglia have shown that a prostate cancer urine test can identify men at 'intermediate risk' who can safely avoid immediate treatment and benefit from 'active surveillance' instead.
Nov 3, 2021
0
5
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study, which examined biopsy samples collected ...
Oct 25, 2021
0
3
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.
Sep 23, 2021
0
9
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC). ...
Sep 20, 2021
0
8
For men with "low-risk" prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal ...
Sep 10, 2021
0
3
